Two vaccines to prevent cervical cancer are nearing approval in the United States and Europe, but they are causing controversy because they are recommended for use in children aged 11 or 12, before they begin sexual activity, Dr Robert Steinbrook, a national correspondent of the New England Journal of Medicine said in a recent edition of the journal (2006;354:1109-12) .
Conservative groups in the US say that use of the vaccine would encourage young people to be promiscuous. The Family Research Council, which earlier said that adolescents should be getting a message about abstinence, later said that it would support use of the vaccines but would oppose efforts to make vaccination mandatory for those attending school.
But conservative organisations may be planning state by state rather than federal campaigns against the vaccines, says a policy review by the Guttmacher Institute, an independent health research organisation (Guttmacher Policy Review 2006; 9:6-9 Gardasil protects against infection with the human papillomavirus types 16 and 18, which cause about 70% of cervical, anal, and genital cancers, and it protects against types 6 and 11, which cause about 90% of genital warts. Gardasil is for women and men. Cervigard is only for women.
Vaccines against cervical cancer provoke US controversy
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Hospitals may have to merge or start cutting back to deal with surplus capacity, doctors have been warned by an expert in health service policy.
An excess number of hospital beds was bringing about changes to the way the NHS operated and because of increasing competition might lead to some hospitals taking over others to survive, doctors heard at a London conference organised by the BMA, entitled Can We Make Sense of System Reform?
Professor Chris Ham of the Health Services Management Centre at the University of Birmingham, and a former adviser to the Labour government, said to about 100 doctors on Tuesday that recent reforms had done a lot to improve patient care but that competition had been reintroduced into the NHS, which would have repercussions.
The reforms that were relevant to both the achievements and the problems included patients' choice, plurality of provision, independent regulation, practice based commissioning, and payment by results-the system whereby hospitals are paid per patient treated rather than in lump sums based on past activity.
The government was keen on a policy of what he called "creative destruction" of the NHS so that change was always on the horizon to force the NHS to keep improving.
"The implications are that the NHS could soon have surplus hospital capacity (in some parts of the country, it already has) and some hospitals may seek to compete aggressively to fill their beds," he said. "Competition for patients will become more intense. Payment by results creates opportunity to move money out of hospitals."
This meant that new relationships would form, such as mergers and acquisitions becoming more common and hospitals taking over neighbouring providers. North West London Strategic Health Authority was already claiming it had a surplus of 600 acute hospital beds.
Practice based commissioning remained a problem, he added, saying, "Commissioning remains the Achilles' heel. Our current model of primary care is not particularly well designed to… drive radical change."
The potential impact of system reform, he claimed, was: G About 15% of elective activity will be in the independent sector G About 5% of diagnostic activity will be in the independent sector G A third of outpatient activity could move out of hospital.
The BMA said at a later press briefing that the NHS was not in crisis, but there was a "chaos of policy" that was making the budget deficits currently being faced by several trusts all the harder to sort out.
Government favours "creative destruction" of the NHS
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Aspirin will loom large in World Cup shindig
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A giant aspirin weighing 25 tonnes has been erected in Berlin as part of an exhibition designed to show visitors to this year's World Cup football tournament how Germany has helped to make the world a better place.
The metal aspirin, nearly 10 m in diameter, fronts the "medical milestones" section of Berlin's new, government funded outdoor display called Walk of Ideas.
Aspirin was first produced by the German company Bayer in 1897.
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